
    
      Patients for who a pancreatic stent placement is indicated will be excluded from the study.

      The aims of this study are: 1) to study in a pathophysiologic point of view the activation of
      HO-1 by hemin in human and its protective effect in post-ERCP acute pancreatitis incidence.
      2) to use the human situation of post-ERCP acute pancreatitis as early pancreatitis model to
      study the administration of hemin as treatment of acute pancreatitis in general.
    
  